‌

US Patent 11353458 Prognostic method

Patent 11353458 was granted and assigned to GlaxoSmithKline on June, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

GlaxoSmithKline

0

Current Assignee

GlaxoSmithKline

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Danton Bounds0

Katherine (Nee Sully) Nevin0

Kwee L. Yong0

Laura M. Seestaller-Wehr0

Lee McCahon0

Lydia Lee0

Manuel Rodriguez-Justo0

Patrick A. Mayes0

...

Date of Patent

June 7, 2022

0

Patent Application Number

157716220

Date Filed

October 28, 2016

0

Patent Citations Received

US Patent 11840575 Engineered immune cells targeting BCMA and their uses thereof

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

G01N 2333/70578

0

Methods are provided for determining prognosis of multiple myeloma in a patient by measuring expression of BCMA in a sample. Also provided are methods for treating multiple myeloma by measuring expression of BCMA in a sample and administering an effective amount of an antigen binding protein that binds BCMA. Also provided are kits for measuring BCMA expression in a sample.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11353458 Prognostic method

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool